SCHEDULE: Keros Therapeutics: ADAR1 Demands Board Engagement

ADAR1 Capital Management, Keros Therapeutics' largest stockholder, is pressing the Board for engagement on strategy, capital allocation, and board refreshment, threatening a proxy fight.

Summary

• ADAR1 Capital Management, with approximately 13.3% of Keros Therapeutics' outstanding shares (5,389,264 shares), is the largest stockholder.
• ADAR1 is disappointed with the Board's refusal to engage directly on strategy, capital allocation, and Board refreshment.
• ADAR1 believes Keros is significantly undervalued, supported by its large cash balance and the net present value of the Takeda partnership for elritercept.
• ADAR1 urges the Company to promptly communicate a clear plan for returning $375 million in excess capital, specifically via a special dividend.
• If the Board continues to refuse engagement, ADAR1 will seek to elect new directors at the next Annual Meeting.
• ADAR1 cautions the Board against making changes to composition or strategy without major stockholder input.

Sentiment

Score: 3

Explanation: The sentiment is negative from the perspective of the activist investor, ADAR1 Capital Management, due to the Board's refusal to engage and the lack of progress on capital return. This indicates potential conflict and uncertainty for the company.

Positives

• Keros Therapeutics has a large cash balance, which ADAR1 believes supports a higher valuation.
• The Takeda partnership for elritercept is believed by ADAR1 to have significant net present value.
• ADAR1 Capital Management, as the largest stockholder, is actively advocating for shareholder value and improved corporate governance.

Negatives

• The Board has refused to engage directly with ADAR1 Capital Management, despite ADAR1 being the largest stockholder.
• There is a lack of follow-through and update on the previously announced plan to return $375 million in excess capital.
• Broad stockholder dissatisfaction was evident in the results of the 2025 Annual Meeting.
• The Company's stock is significantly undervalued according to ADAR1 Capital Management.

Risks

• Potential for a proxy contest at the next Annual Meeting if the Board does not engage with ADAR1 Capital Management.
• Risk of the Board making strategic or compositional changes without input from major stockholders.
• Continued undervaluation of the Company's stock if current strategic and capital allocation issues are not addressed.
• Shareholder dissatisfaction and potential erosion of investor confidence due to lack of engagement from the Board.

Future Outlook

ADAR1 Capital Management intends to seek to elect new directors at Keros Therapeutics' next annual meeting of stockholders if the Board continues to refuse engagement on strategy, capital allocation, and Board refreshment.

Management Comments

• "We believe Keros is worth significantly more than the price at which its stock trades."
• "Its valuation is supported, in our view, by the Company's large cash balance and the net present value of the Takeda partnership for elritercept, which we believe the Company should distribute to stockholders via CVR."
• "Shareholders have now waited for more than two months without any update on the timing or process for the return of capital."
• "We urge the Company to promptly communicate a clear and detailed plan to return capital, specifically through the declaration of a special dividend."
• "Should the Board continue to refuse our invitations to engage, we will seek to elect new directors at the next Annual Meeting – directors who will embrace their role as fiduciaries and are willing to at least hear the perspectives of stockholders."
• "We caution the Board against making any changes to its composition or to the Company’s strategy without first seeking input from its major stockholders, including ADAR1."

Industry Context

This filing highlights a common dynamic in the biotechnology and life sciences sectors where companies with significant cash reserves and promising pipeline assets (like the Takeda partnership for elritercept) may face activist pressure if their market valuation does not reflect the perceived intrinsic value. Shareholder activism often arises when investors believe management or the board is not effectively unlocking value, particularly through capital allocation or strategic direction.

Comparison to Industry Standards

• The situation reflects a common activist investor strategy seen across industries, where a significant shareholder (ADAR1 with 13.27%) publicly pressures a company's board for strategic changes, capital returns, and governance improvements.
• The demand for a special dividend to distribute excess capital, particularly from a partnership like the Takeda deal, is a tactic often employed by activists in biotech, similar to how Carl Icahn or Starboard Value might push for distributions or asset sales in other sectors.
• The threat of a proxy fight to elect new directors is a standard escalation in shareholder activism, comparable to past campaigns at companies like Procter & Gamble (Nelson Peltz) or DuPont (Trian Fund Management), though Keros is a smaller biotech firm.
• The 'large cash balance' and 'net present value of the Takeda partnership' are specific assets that ADAR1 believes are undervalued, a common theme in biotech where pipeline value is often difficult for the market to fully appreciate without clear strategic direction or capital allocation.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential for increased shareholder value if ADAR1's proposals (e.g., special dividend, strategic reorientation) are adopted. Risk of prolonged uncertainty and potential proxy fight if the Board resists.
• Management/Board: Increased pressure and scrutiny from a major activist investor. Potential for changes in leadership and strategic direction.
• Employees: Indirect impact from potential strategic shifts or changes in company focus.

Next Steps

• ADAR1 Capital Management reiterates its request to meet with Keros Therapeutics' independent directors.
• ADAR1 urges Keros Therapeutics to promptly communicate a clear and detailed plan to return capital, specifically through a special dividend.
• If the Board continues to refuse engagement, ADAR1 will seek to elect new directors at the next Annual Meeting of stockholders.

Key Dates

Recommendation

The filing indicates significant shareholder activism and a potential proxy fight, creating uncertainty. While the activist highlights potential undervaluation and avenues for value creation (cash balance, Takeda partnership, special dividend), the current conflict with the Board introduces risk. Investors should hold to observe how the Board responds to ADAR1's demands and whether a constructive dialogue or a proxy contest materializes, as this will dictate the near-term trajectory.

Keywords

Keros Therapeutics, KROS, ADAR1 Capital Management, Shareholder Activism, Proxy Fight, Corporate Governance, Capital Allocation, Special Dividend, Biotech, Life Sciences, SEC Filing, Schedule 13D